Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jul 22, 2015 4:25pm

127 Views

Post# 23950305

RE:RE:THE PINKS

RVXCF (pinks) had a single trade of 300 shares this morning right around opening at $1.70. RVX.TO dropped a little bit after closing and the RVXCF trade happened before this. At closing, bid is $1.53 and ask is $1.56. No one is trading. The price will correct and better align with RVX.TO when trading is more active. I see the same thing happen with BiOasis between the BTI.V Canadian listing and BIOAF in the US.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity